NDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
4/8 — Partial
Priority Review
NIPENT (pentostatin) by Pfizer is nucleic acid synthesis inhibitors [moa]. First approved in 1991.
Drug data last refreshed 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIPENT (pentostatin) is a nucleoside metabolic inhibitor approved in 1991 for chronic lymphocytic leukemia, lymphomas, and other hematologic malignancies. It works by inhibiting nucleic acid synthesis, disrupting DNA replication in rapidly dividing cancer cells. The drug is administered by injection and targets a broad range of blood cancers and immune disorders including graft-versus-host disease.
$0.092BPart D
LOE ApproachingDeclining
Mature oncology asset approaching loss of exclusivity with minimal active team and limited growth opportunity; career moves typically flow to emerging pipeline candidates.
Mechanism of Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Class:
Nucleoside Metabolic Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Started Sep 2011
47 enrolled
Chronic Lymphocytic Leukemia
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Started May 2011
10 enrolled
Chronic Lymphocytic LeukemiaB-Cell Non-Hodgkin's Lymphoma
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
Started Jul 2006
14 enrolled
Hematologic Malignancies
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
Started Jun 2005
100 enrolled
Lymphoma
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Started May 2005
49 enrolled
LeukemiaLymphoma
Worked on NIPENT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.